Results 61 to 70 of about 2,564 (175)

Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan

Digestive Endoscopy, Volume 38, Issue 3, March 2026.
ABSTRACT Objectives Sedation during colonoscopy is becoming increasingly important. Remimazolam, an ultra‐short‐acting benzodiazepine, has a shorter pharmacokinetic half‐life than that of midazolam. This study examined whether remimazolam provides superior sedation during colonoscopy in Japanese patients.
Daisuke Yamaguchi, Ryoji Ichijima, Hisatomo Ikehara, Yosuke Minoda, Mitsuru Esaki, Ayako Takamori, Akiyoshi Yoh, Moeko Shirouzu, Kento Sadashima, Yutaro Fujimura, Takuya Shimamura, Hironobu Takedomi, Takashi Akutagawa, Nanae Tsuruoka, Yasuhisa Sakata, Takuya Wada, Chika Kusano, Ryo Shimoda, Motohiro Esaki   +18 more
wiley   +1 more source

Real‐World Evaluation of Remimazolam for Sedation During Gastrointestinal Endoscopy: Efficacy, Safety, and Risk Factors

JGH Open, Volume 10, Issue 2, February 2026.
ABSTRACT Background and Aim Remimazolam is a benzodiazepine receptor agonist intravenous anesthetic. This study aimed to evaluate the efficacy and safety of remimazolam for sedation during gastrointestinal endoscopy using real‐world clinical data.
Hinako Sakurai, Kurato Miyazaki, Atsushi Nakayama, Motoki Sasaki, Mai Oowada, Misaki Sugawara, Yuki Kubo, Rei Mizobe, Ai Katsumi, Maya Ishizawa, Yuri Imura, Shoma Murata, Daisuke Minezaki, Kentaro Iwata, Anna Tojo, Teppei Masunaga, Kumiko Kirita, Mari Mizutani, Michiko Nishikawa, Yusaku Takatori, Teppei Akimoto, Shintaro Kawasaki, Noriko Matsuura, Hideomi Tomida, Tomohisa Sujino, Kaoru Takabayashi, Kanai Takanori, Naohisa Yahagi, Motohiko Kato   +28 more
wiley   +1 more source

Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background and Aims Remimazolam, a new ultra‐short‐acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those
Yehyun Park, Jun Kyu Lee, Kwang Hyuck Lee, Taejun Kim, Sun Hyung Kang, Dong‐Won Ahn, Sung Bum Kim, Seong‐Jung Kim   +7 more
wiley   +1 more source

Economic benefits of remimazolam compared to midazolam and propofol for procedural sedation in colonoscopies and bronchoscopies

, 2023
Background: Sedation is common practice in endoscopic procedures to suppress a patient’s level of consciousness while maintaining the cardio-respiratory function.
Lisbeth Kattenhøj (15207458), Mikkel H. Pedersen (12306252), Anne Danø (15207452), Emma Munk (15207461), Ebbe Englev (15207455)   +4 more
core   +1 more source

Comparative analysis of the therapeutic efficacy of remimazolam tosylate and propofol in older adults undergoing painless endoscopic retrograde cholangiopancreatography

Frontiers in Pharmacology
ObjectiveThe aim of this study is to conduct a comparative analysis of the therapeutic outcomes associated with the administration of remimazolam and propofol during painless endoscopic retrograde cholangiopancreatography (ERCP) procedures in older ...
Yu-quan Tian, Di-kun Chen, He-ming Zhang, Yong-mei Sun   +3 more
doaj   +1 more source

Remimazolam anaphylaxis in a patient not allergic to brotizolam: a case report and literature review

BMC Anesthesiology
Background Remimazolam is a recently developed, ultrashort-acting benzodiazepine that is used as a general anesthetic. Some cases of remimazolam anaphylaxis have been reported, but its characteristics are not fully understood.
Toshihiro Nakai, Eisuke Kako, Haruko Ota, MinHye So, Kazuya Sobue   +4 more
doaj   +1 more source

Quality of Recovery After General Anesthesia with Remimazolam in Patients’ Undergoing Urologic Surgery: A Randomized Controlled Trial Comparing Remimazolam with Propofol

Drug Design, Development and Therapy, 2022
Yuanyuan Mao, Jin Guo, Jingjing Yuan, Erxian Zhao, Jianjun Yang Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence: Jianjun Yang,
Mao Y, Guo J, Yuan J, Zhao E, Yang J
doaj  

Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system

, 2019
Nora Freyer,1 Fanny Knöspel,1 Georg Damm,2 Selina Greuel,1 Christin Schneider,1 Daniel Seehofer,2 Thomas Stöhr,3 Karl-Uwe Petersen,3 Katrin Zeilinger1 1Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité &ndash ...
Freyer N, Stöhr T, Zeilinger K, Schneider C, Petersen KU, Greuel S, Damm G, Seehofer D, Knöspel F   +8 more
core  

Remimazolam: First Approval

, 2020
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflict of interest:  During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on ...
Susan J. Keam (6594447)
core   +1 more source

Remimazolam attenuates traumatic brain injury-induced acute lung injury by suppressing pulmonary epithelial pyroptosis

Journal of Neuroinflammation
Background and objectives TBI-induced acute lung injury (TBI-ALI), with an incidence rate of 22-25%, represents a critical determinant of secondary mortality. Remimazolam is a novel sedative that has shown potential for anti-inflammatory effects. However,
Chang Sun, Yi Zhang, Jiahan Wang, Bailun Wang, Angran Gu, Yuelan Wang, Changping Gu   +6 more
doaj   +1 more source